## Prophylactic Thyroidectomy in RET-Positive Carriers **Key Point:** Prophylactic thyroidectomy in RET proto-oncogene mutation carriers is a cornerstone of MTC prevention in Multiple Endocrine Neoplasia type 2 (MEN 2) syndromes. However, the extent of lymph node dissection depends on risk stratification and biochemical evidence of disease. ### RET Mutation Risk Stratification (ATA Guidelines) | Risk Level | RET Mutations | Age at Surgery | Additional Procedures | | --- | --- | --- | --- | | **A (Lowest)** | M918T exon 16, A883F exon 15 | Before age 5–10 years | Thyroidectomy only; no lymph node dissection | | **B (Intermediate)** | Codon 634 mutations (exon 11) | Before age 5 years | Thyroidectomy ± central lymph node dissection if biochemical evidence | | **C (Highest)** | Multiple exon 11 mutations, exon 13–15 | Before age 1 year | Thyroidectomy + central lymph node dissection if elevated calcitonin | **High-Yield:** Risk stratification is **critical**. Not all RET-positive carriers require the same surgical approach or timing. ### Why Central Lymph Node Dissection Is NOT Routine in All RET-Positive Carriers **Clinical Pearl:** Central lymph node dissection (CLND) is reserved for: 1. **Biochemical evidence of disease** (elevated serum calcitonin or calcitonin stimulation test positive) 2. **High-risk RET mutations** (ATA risk level C) 3. **Imaging evidence** of lymph node involvement In **low-risk RET mutations** (ATA level A) and **asymptomatic carriers with normal calcitonin**, routine CLND at prophylactic thyroidectomy is **NOT recommended** because: - It increases morbidity (hypoparathyroidism, RLN injury) - Lymph node involvement is rare in these low-risk groups - No survival benefit is demonstrated **Warning:** Aggressive lymph node dissection in all RET-positive carriers increases complications without proportional benefit. The approach must be **risk-stratified**. ### Why the Other Statements Are Correct **Statement 1 (Correct):** All RET-positive family members should undergo prophylactic thyroidectomy. Age varies by risk level, but the principle of surgery in all carriers is established. **Statement 2 (Correct):** ATA risk stratification (A, B, C) directly determines: - Age at surgery (ranging from <1 year to 10 years) - Extent of lymph node dissection - Preoperative biochemical testing requirements **Statement 3 (Correct):** Prophylactic thyroidectomy in childhood RET-positive carriers has transformed MTC from a lethal disease (historically 50% mortality by age 50) to near-complete prevention of MTC development when performed before age 5–10 years, depending on risk level. ```mermaid flowchart TD A[RET-positive family member]:::outcome --> B{ATA Risk Level?}:::decision B -->|Level A<br/>Low risk| C[Thyroidectomy<br/>Age 5-10 years]:::action B -->|Level B<br/>Intermediate| D[Thyroidectomy<br/>Age 5 years]:::action B -->|Level C<br/>Highest| E[Thyroidectomy<br/>Age < 1 year]:::action C --> F{Calcitonin elevated?}:::decision D --> F E --> G[CLND if calcitonin elevated]:::action F -->|No| H[Thyroidectomy only]:::action F -->|Yes| I[Thyroidectomy + CLND]:::action H --> J[Lifelong follow-up]:::outcome I --> J ```
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.